Other languages Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Market Closed - Nasdaq Other stock markets 02:00:01 03/05/2024 am IST			5-day change	1st Jan Change
4.76 ^USD	-1.45%		+7.86%	-29.97%

09/04	Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	CI
03/04	Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09/04
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	03/04
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02/11
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/23/19
Top Midday Gainers	13/23/13
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
Sector Update: Healthcare	17/22/17
Top Midday Decliners	17/22/17
Synaptogenix Shares Decline After Proposed Alzheimer's Disease Treatment Misses Primary Endpoint in Phase 2 Study	16/22/16
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	16/22/16
Synaptogenix Announces $15 Million Private Placement	18/22/18
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	06/22/06
Synaptogenix Doses First Patient in Alzheimer's Disease Dose Optimization Clinical Trial; Shares Rise	20/22/20
Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data	20/22/20
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14
Synaptogenix Completes Patient Enrollment in Phase 2b Trial of Drug Candidate for Alzheimer's Disease	19/22/19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Other languages

Filters